View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
June 25, 2020updated 27 Oct 2021 11:55am

Moderna and Catalent team up on Covid-19 vaccine manufacturing

Moderna has collaborated with manufacturing solutions provider Catalent for large-scale, commercial fill-finish manufacturing of its Covid-19 vaccine candidate, mRNA-1273.

Moderna has collaborated with manufacturing solutions provider Catalent for large-scale, commercial fill-finish manufacturing of its Covid-19 vaccine candidate, mRNA-1273.

The manufacturing will be carried out at Catalent’s biologics facility in Bloomington, Indiana, US.

Catalent agreed to deliver vial filling and packaging capacity, and additional staffing required for 24×7 manufacturing activities at the site to facilitate the production of an initial 100 million doses.

The aim is to begin the supply of the vaccine candidate to the US market beginning in the third quarter of this year. The companies are also in talks for the finish-fill capacity to continue producing millions of additional doses.

As part of the collaboration, Catalent will also offer clinical supply services from its facilities in Philadelphia, Pennsylvania, including packaging and labelling.

In addition, the company will provide storage and distribution services for Moderna’s Phase III clinical trial of the vaccine candidate.

Catalent chair and CEO John Chiminski said: “Catalent’s proven expertise in manufacturing scale-up and commercial production are well suited to support Moderna’s efforts to prepare for wide-scale supply of this vaccine candidate so that it is available if appropriate to address the pandemic.”

Catalent’s 875,000ft2 biologics facility in Bloomington will carry out this vial filling work using barrier isolator technology. Also, Moderna will utilise the site’s recent packaging expansion.

Currently in Phase II trial, Moderna’s Covid-19 vaccine candidate secured fast-track designation from the US Food and Drug Administration (FDA) last month. The vaccine is expected to enter Phase III trials next month.

In May, Moderna signed a ten-year agreement with Lonza for large-scale manufacture of its Covid-19 vaccine candidate and other products in the future.

Under the agreement, the companies will create manufacturing suites at Lonza’s facilities in the US and Switzerland to produce mRNA-1273.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology